SCHEMBL649437

SCHEMBL649437

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
CRHR1 P34998 5/20 0.38
TSHR P16473 2/20 0.38
HSD11B1 P28845 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
NR1H3 Q13133 1/20 0.35
P2RX7 Q99572 1/20 0.34
CXCR3 P49682 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MMP13 P45452 1/20 0.34
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134641 0.94 C5AR1 (0.45) C5AR1UBE2MDCUN1D1CRHR1TSHR
SCHEMBL5136054 0.93 C5AR1 (0.42) C5AR1UBE2MDCUN1D1TSHRCXCR3
SCHEMBL650670 0.93 C5AR1 (0.46) C5AR1UBE2MDCUN1D1CRHR1TSHR
SCHEMBL5134962 0.91 C5AR1 (0.48) C5AR1CRHR1TSHRHSD11B1NR1H3
SCHEMBL1912954 0.90 C5AR1 (0.45) C5AR1UBE2MDCUN1D1CRHR1TSHR
SCHEMBL5135207 0.90 C5AR1 (0.42) C5AR1UBE2MDCUN1D1CRHR1TSHR
SCHEMBL652185 0.89 C5AR1 (0.63) C5AR1UBE2MDCUN1D1TSHRKDM4E
SCHEMBL648503 0.88 C5AR1 (0.47) C5AR1UBE2MDCUN1D1CRHR1TSHR
SCHEMBL648089 0.88 C5AR1 (0.47) C5AR1CRHR1TSHRHSD11B1NR1H3
SCHEMBL5135213 0.87 C5AR1 (0.42) C5AR1UBE2MDCUN1D1CRHR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed